Fee(2)(3)Common Stock, $0.001 par value per share$73,312,500$8,497.00(1)Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.(2)Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.(3)A registration fee of $7,998 was previously paid in connection with the Registration Statement, and the additional amount of $499 is being paid herewith.The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
strategy to achieve this goal include the following:•Pursue a broad development strategy for our lead product candidate, ALRN-6924, as a monotherapy or combination therapy across multiple oncology indications.•Rapidly advance ALRN-6924 through clinical development and regulatory approval.•Maximize the global commercial value of ALRN-6924 and other product candidates.•Leverage our proprietary stapled peptide technology to develop additional product candidates across oncology and other diseases with unmet medical need.4Table of Contents•Maintain our leading position in stapled peptides by continuing to develop our proprietary platform.Risks
trials and all of our other product candidates are in preclinical research.•We believe that the net proceeds from this offering, together with our existing cash, cash equivalents and investments, will enable us to fund our operating expenses and capital expenditure requirements through the
effect of binding to and simultaneously disrupting the interactions of MDMX and MDM2 with WT p53 in cancer patients has not been established in clinical trials.•If we experience delays or difficulties in the enrollment of patients in clinical trials, we may not be able to initiate or complete clinical trials for our product candidates on a timely basis.•The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.•If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs, experience
including by failing to meet deadlines for the completion of such trials, research and studies, we could be delayed in our clinical development activities or in our efforts to obtain marketing approval of our product candidates.5Table of Contents•Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, including ALRN-6924, their
indicative of results that should be expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any full year.Year Ended December 31,Three MonthsEnded March 31,2015201620162017(in thousands, except per share data)Statement of Operations Data:Revenue$—$—$—$—Operating expenses:Research and development7,83210,2762,4932,942General and administrative5,0597,8931,4461,647Total operating expenses12,89118,1693,9394,589Loss from operations(12,891)(18,169)(3,939)(4,589)Interest and other income13461432Net loss(12,878)(18,123)(3,925)(4,557)Accretion of redeemable convertible preferred stock to redemption value(71)(75)(18)(20)Net loss attributable to common stockholders$(12,949)$(18,198)$(3,943)$(4,577)Net loss per share attributable to common stockholders—basic and diluted(1)$(32.31)$(42.35)$(9.25)$(10.58)Weighted average common shares outstanding—basic and diluted(1)401430426433Pro forma net loss per share attributable to common stockholders—basic and diluted
the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.As of March 31, 2017ActualPro FormaPro FormaAs Adjusted(2)(in thousands)Balance Sheet Data:Cash, cash equivalents and investments$15,294$15,294$68,934Working capital(1)13,11113,11166,956Total assets17,15517,15570,590Redeemable convertible preferred stock130,391——Total stockholders’ equity (deficit)(116,111)14,28067,920(1)We define working capital as current assets less current liabilities.(2)A $1.00 increase or decrease in the assumed initial public offering price of $16.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro
increase substantially if and as we:•conduct our current and future clinical trials and additional preclinical research of ALRN-6924;•initiate and continue research and preclinical and clinical development of our other product candidates;•seek to identify additional product candidates;•seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;•establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;•require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization;•maintain, expand and protect our intellectual property portfolio;•acquire or in-license other drugs and technologies;•hire and retain additional clinical, quality control and scientific personnel;•build out new facilities or expand existing facilities to support our ongoing development activity; and•add operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our transition to a public company.11Table of ContentsTo become and remain profitable, we must develop, obtain approval for and eventually
If we are unable to raise capital when needed or on12Table of Contentsattractive terms, we may be forced to delay, reduce and/or eliminate our research and drug development programs or future commercialization efforts.We plan to use the net proceeds from this offering to fund our ongoing clinical trials of ALRN-6924 and additional research and clinical
Our future capital requirements will depend on many factors, including:•the scope, progress, results and costs of our current and future clinical trials and additional preclinical research of ALRN-6924;•the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for our other product candidates;•the number of future product candidates that we pursue and their development requirements;•the costs, timing and outcome of regulatory review of our product candidates;•our ability to establish and maintain collaborations on favorable terms, if at all;•the success of any collaborations that we may enter into with third parties;•the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we currently have no commitments or
such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;•the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;13Table of Contents•the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;•our headcount growth and associated costs as we expand our business operations and our research and development activities; and•the costs of operating as a public company.Our product candidates, if approved, may not
purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our product candidates.We expect our expenses to increase in connection with our planned operations.
may never receive such marketing approvals.The success of ALRN-6924 will depend on several factors, including the following:•successful and timely completion of our ongoing clinical trials of ALRN-6924;•initiation and successful patient enrollment and completion of additional clinical trials on a timely basis;•safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority for marketing approval;•timely receipt of marketing approvals for both ALRN-6924 and any required companion diagnostic from applicable regulatory authorities;•the performance of our future collaborators, if any;•the extent of any required post-marketing approval commitments to applicable regulatory authorities;•establishment of supply arrangements with third-party raw materials and drug product suppliers and manufacturers;•establishment of scaled production arrangements with third-party manufacturers to obtain finished products that are appropriately packaged for sale;•obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;•protection of our rights in our intellectual property portfolio, including our licensed intellectual property;•successful launch of commercial sales following any marketing approval;•a continued acceptable safety profile following any marketing approval;•commercial acceptance by patients, the medical community and third-party payors; and•our ability to compete with other therapies.We do not have complete control over many of
no assurance that the FDA or non-U.S. regulatory authorities will consider our future clinical trials to be sufficient to serve as the basis for approval of one of our product candidates for any indication.
product candidate than we expect prior to its approval, we will need substantial additional funds and there is no assurance that the results of any such additional clinical trials will be sufficient for approval.Clinical drug development is a lengthy and expensive process, with an uncertain outcome.
varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.We do not know whether ongoing clinical trials will be completed on schedule or at all, or whether future clinical trials will begin on time,
experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:•we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;18Table of Contents•clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;•the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these
contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:•incur unplanned costs;•be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;•obtain marketing approval in some countries and not in others;•obtain marketing approval for indications or patient populations that are not as broad as intended or desired;•obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;•be subject to additional post-marketing testing requirements; or•have the drug removed from the market after obtaining marketing approval.Our drug
any future collaborators, an institutional review board, or IRB, or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in the delay or denial of marketing approval by the FDA
believed or causes undesirable side effects that were not previously identified, a number of potentially significant negative consequences could result, including:•regulatory authorities may withdraw their approval of the drug or seize the drug;•we, or any future collaborators, may be required to recall the drug, change the way the drug is administered or conduct additional clinical trials;•additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug;•we may be subject to fines, injunctions or the imposition of civil or criminal penalties;•regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication;•we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;•we, or any future collaborators, could be sued and held liable for harm caused to patients;•the drug may become less competitive; and•our reputation may suffer.Any of these events could have a material and adverse effect on
commercial sale, will depend on a number of factors, including:•the efficacy and safety of the product;•the potential advantages of the product compared to competitive therapies;23Table of Contents•the prevalence and severity of any side effects;•whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;•our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;•the product’s convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try, and of physicians to prescribe, the product;•limitations or warnings, including distribution or use restrictions contained in the product’s approved labeling;•the strength of sales, marketing and distribution support;•changes in the standard of care for the targeted indications for the product; and•availability and amount of coverage and reimbursement from government payors, managed care plans and other third-party payors.If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our
inhibit our efforts to commercialize our drugs on our own include:•our inability to recruit and retain adequate numbers of effective sales and marketing personnel;•the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs;•the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive drug lines;24Table of Contents•unforeseen costs and expenses associated with creating an independent sales and marketing organization; and•inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies.If we enter into arrangements with third parties to perform sales and marketing services, our revenues from the sale of drugs or the
If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.The pharmaceutical and biotechnology industries generally, and the cancer drug sector specifically, are highly competitive and
addition to currently marketed therapies, there are also a number of drugs in late-stage clinical development to treat cancer, including the indications for which we are developing product candidates.
claims may result in:•decreased demand for any product candidates or drugs that we may develop;•injury to our reputation and significant negative media attention;•withdrawal of clinical trial participants;•significant costs to defend the related litigation;•substantial monetary awards to trial participants or patients;•loss of revenue;•reduced resources of our management to pursue our business strategy; and•the inability to commercialize any drugs that we may develop.We currently hold clinical
collaborators, may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval.
part of such third parties could delay clinical development or marketing approval of our product candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue from sales of drugs.We contract with third parties for the manufacture of our product candidates for preclinical studies and, in the case of ALRN-6924, our ongoing clinical
adversely affect our future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis.Although we currently plan to retain all commercial rights to ALRN-6924 and our other stapled peptide product candidates, we may enter into strategic
would pose the following risks to us:•collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;•collaborators may not perform their obligations as expected;•collaborators may not pursue development, marketing and/or commercialization of our product candidates or may elect not to continue or renew development, marketing or commercialization programs based on clinical trial
information or expose us to potential litigation;•collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;•we may lose certain valuable rights under circumstances identified in any collaboration arrangement that we enter into, such as if we undergo a change of control;•collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development, marketing and/or commercialization of the applicable product candidates;•collaborators may learn about our discoveries, data, proprietary information, trade secrets, or compounds and use this knowledge to compete with us in the future; and•the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers.Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all.If we decide to seek to establish collaborations, but are not able to establish those collaborations, we may have to alter our development and
Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of
patent rights;•we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions;35Table of Contents•others may independently develop similar or alternative technologies or duplicate any of our technologies;•it is possible that our pending patent applications will not result in issued patents;•it is possible that there are prior public disclosures that could invalidate our or our licensors’ patents, as the case may be, or parts of our or their patents;•it is possible that others may circumvent our owned or in-licensed patents;•it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours;•the laws of foreign countries may not protect our or our licensors’, as the case may be, proprietary rights to the same extent as the laws of the United States;•the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;•our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties;•the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or
patents or other intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our proprietary
product candidates could fail to receive marketing approval for many reasons, including the following:•the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;•we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;•the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;•we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;•the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;•the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain marketing approval in the United States or elsewhere;•the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;41Table of Contents•the FDA or comparable foreign regulatory authorities may fail to approve any companion diagnostics that may be required in connection with approval of our therapeutic product candidates; and•the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain marketing approval
Thus, we, and any collaborators we may have in the future, may not be able to promote any drugs we develop for indications or uses for which they are not approved.The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or
addition, later discovery of previously unknown adverse events or other problems with our drugs or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:•litigation involving patients taking our drug;•restrictions on such drugs, manufacturers or manufacturing processes;•restrictions on the labeling or marketing of a drug;•restrictions on drug distribution or use;•requirements to conduct post-marketing studies or clinical trials;•warning letters or untitled letters;•withdrawal of the drugs from the market;•refusal to approve pending applications or supplements to approved applications that we submit;•recall of drugs;•fines, restitution or disgorgement of profits or revenues;•suspension or withdrawal of marketing approvals;•damage to relationships with any potential collaborators;•restrictions on coverage by third-party payors;45Table of Contents•unfavorable press coverage and damage to our reputation;•refusal to permit the import or export of drugs;•drug seizure; or•injunctions or the imposition of civil or criminal penalties.Recently enacted and future legislation,
The provisions of the Affordable Care Act of potential importance to our product candidates are the following:•an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;•an increase in the statutory minimum Medicaid rebates a manufacturer must pay under the Medicaid Drug Rebate Program and extension of the rebate program to individuals enrolled in Medicaid managed care organizations;•expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance;•a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs and therapeutic biologics to eligible
beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs and therapeutic biologics to be covered under Medicare Part D;•extension of manufacturers’ Medicaid rebate liability;•expansion of eligibility criteria for Medicaid programs;•expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;46Table of Contents•new requirements to report certain financial arrangements with physicians and certain others, including reporting “transfers of value” made or distributed to prescribers and other healthcare providers and
reporting investment interests held by physicians and their immediate family members;•a new requirement to annually report drug samples that manufacturers and distributors provide to physicians;•a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and•a new Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription
The market price for our common stock may be influenced by many factors, including:•the timing and results of clinical trials of ALRN-6924 and any of our other product candidates;•regulatory actions with respect to our product candidates or our competitors’ products and product candidates;•the success of existing or new competitive products or technologies;•announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;55Table of Contents•establishment or termination of collaborations for our product candidates or development programs;•failure or discontinuation of any of our development programs;•results of clinical trials of product candidates of our competitors;•regulatory or legal developments in the United States and other countries;•developments or disputes concerning patent applications, issued patents or other proprietary rights;•the recruitment or departure of key personnel;•the level of expenses related to any of our product candidates or development programs;•the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;•actual or anticipated changes in estimates as to financial results or development timelines;•announcement or expectation of additional financing efforts;•sales of our common stock by us, our insiders or other stockholders;•variations in our financial results or those of companies that are perceived to be similar to us;•changes in estimates or recommendations by securities analysts, if any, that cover our stock;•changes in the structure of healthcare payment systems;•market conditions in the pharmaceutical and biotechnology sectors;•general economic, industry and market conditions; and•the other factors described in this “Risk Factors” section.We could be subject to securities
words.These forward-looking statements include, among other things, statements about:•our plans to develop and commercialize ALRN-6924 and other product candidates, including the potential benefits thereof;•our ongoing and future clinical trials for ALRN-6924, whether conducted by us or by any future collaborators, including the timing of initiation of these trials and of the anticipated results;•the timing of and our ability to obtain and maintain marketing approvals for our product candidates;•the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval;•our commercialization, marketing and manufacturing capabilities and strategy;•our intellectual property position and strategy;•our ability to identify additional product candidates with significant commercial potential;•our plans to enter into collaborations for the development and commercialization of product candidates;•the potential benefits of any future collaboration;•our expectations related to the use of proceeds from this offering;•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;•developments relating to our competitors and our industry; and•the impact of government laws and regulations.We may not actually achieve the plans,
losses for at least the next several years.We anticipate that our expenses will increase substantially if and as we:•conduct our current and future clinical trials and additional preclinical research of ALRN-6924;70Table of Contents•initiate and continue research and preclinical and clinical development of our other product candidates;•seek to identify additional product candidates;•seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;•establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;•require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization;•maintain, expand and protect our intellectual property portfolio;•acquire or in-license other drugs and technologies;•hire and retain additional clinical, quality control and scientific personnel; and•add operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our transition to a public company.In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant
activities that we may conduct;•uncertainties in clinical trial design and patient enrollment rates;•significant and changing government regulation and regulatory guidance;•the timing and receipt of any marketing approvals; and•the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in
board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including:•the prices at which we sold shares of preferred stock and the superior rights and preferences of the preferred stock relative to our common stock at the time of each grant;•the progress of our research and development programs, including the status and results of preclinical studies and clinical trials for our product candidates;•our stage of development and commercialization and our business strategy;•external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry;•our financial position, including cash on hand, and our historical and forecasted performance and operating results;•the lack of an active public market for our common stock and our preferred stock;•the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company in light of prevailing market conditions; and•the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry.76Table of ContentsThe assumptions underlying these valuations represented management’s best estimate, which
expenses will increase substantially if and as we:•conduct our current and future clinical trials and additional preclinical research of ALRN-6924;81Table of Contents•initiate and continue research and preclinical and clinical development of our other product candidates;•seek to identify additional product candidates;•seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;•establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;•require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization;•maintain, expand and protect our intellectual property portfolio;•acquire or in-license other drugs and technologies;•hire and retain additional clinical, quality control and scientific personnel;•build out new facilities or expand existing facilities to support our ongoing development activity; and•add operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our transition to a public company.As of March 31, 2017, we had cash, cash equivalents and investments of $15.3 million.
factors, including:•the scope, progress, results and costs of our current and future clinical trials and additional preclinical research of ALRN-6924;•the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for our other product candidates;•the number of future product candidates that we pursue and their development requirements;•the costs, timing and outcome of regulatory review of our product candidates;•our ability to establish and maintain collaborations on favorable terms, if at all;•the success of any collaborations that we may enter into with third parties;82Table of Contents•the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we currently have no commitments or
agreements to complete any such transactions;•the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that
agreements to complete any such transactions;•the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that
such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;•the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;•the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;•our headcount growth and associated costs as we expand our business operations and our research and development activities; and•the costs of operating as a public company.Developing pharmaceutical products, including
conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any product
restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:•completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s good laboratory practice, or GLP, regulations;•submission to the FDA of an IND, which must take effect before human clinical trials may begin;•approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;•performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug product for each proposed indication;•preparation and submission to the FDA of an NDA requesting marketing for one or more proposed indications;•review by an FDA advisory committee, where appropriate or if applicable;•satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing